Search Page

1

Cite

Share

Importance of adiponectin activity in the pathogenesis of Alzheimer's disease.

Waragai M, Ho G, Takamatsu Y, Sekiyama K, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Waragai M, et al. Among authors: sekiyama k. Ann Clin Transl Neurol. 2017 Jul 11;4(8):591-600. doi: 10.1002/acn3.436. eCollection 2017 Aug. Ann Clin Transl Neurol. 2017. PMID: 28812049 Free PMC article. Review.

Cite

Share

2

Cite

Share

Biomarkers for the diagnosis and management of Parkinson's disease.

Waragai M, Sekiyama K, Fujita M, Tokuda T, Hashimoto M. Waragai M, et al. Among authors: sekiyama k. Expert Opin Med Diagn. 2013 Jan;7(1):71-83. doi: 10.1517/17530059.2013.733694. Epub 2012 Nov 4. Expert Opin Med Diagn. 2013. PMID: 23530844 Review.

Cite

Share

3

Cite

Share

Role of genomics in translational research for Parkinson's disease.

Sekiyama K, Takamatsu Y, Waragai M, Hashimoto M. Sekiyama K, et al. Biochem Biophys Res Commun. 2014 Sep 19;452(2):226-35. doi: 10.1016/j.bbrc.2014.06.028. Epub 2014 Jun 17. Biochem Biophys Res Commun. 2014. PMID: 24950403 Review.

Cite

Share

4

Cite

Share

Protection against neurodegenerative disease on Earth and in space.

Takamatsu Y, Koike W, Takenouchi T, Sugama S, Wei J, Waragai M, Sekiyama K, Hashimoto M. Takamatsu Y, et al. Among authors: sekiyama k. NPJ Microgravity. 2016 Apr 7;2:16013. doi: 10.1038/npjmgrav.2016.13. eCollection 2016. NPJ Microgravity. 2016. PMID: 28725728 Free PMC article.

Cite

Share

5

Cite

Share

Diversity of mitochondrial pathology in a mouse model of axonal degeneration in synucleinopathies.

Sekigawa A, Takamatsu Y, Sekiyama K, Takenouchi T, Sugama S, Waragai M, Fujita M, Hashimoto M. Sekigawa A, et al. Among authors: sekiyama k. Oxid Med Cell Longev. 2013;2013:817807. doi: 10.1155/2013/817807. Epub 2013 Mar 14. Oxid Med Cell Longev. 2013. PMID: 23577227 Free PMC article. Review.

Cite

Share

6

Cite

Share

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.

Sekigawa A, Takamatsu Y, Sekiyama K, Hashimoto M. Sekigawa A, et al. Among authors: sekiyama k. Biomolecules. 2015 May 19;5(2):1000-11. doi: 10.3390/biom5021000. Biomolecules. 2015. PMID: 25996784 Free PMC article. Review.

Cite

Share

7

Cite

Share

Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies.

Fujita M, Sekigawa A, Sekiyama K, Takamatsu Y, Hashimoto M. Fujita M, et al. Among authors: sekiyama k. Int J Mol Sci. 2012;13(9):11584-92. doi: 10.3390/ijms130911584. Epub 2012 Sep 14. Int J Mol Sci. 2012. PMID: 23109872 Free PMC article. Review.

Cite

Share

8

Cite

Share

α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.

Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M. Waragai M, et al. Among authors: sekiyama k. Int J Mol Sci. 2010 Oct 29;11(11):4257-66. doi: 10.3390/ijms11114257. Int J Mol Sci. 2010. PMID: 21151436 Free PMC article. Review.

Cite

Share

9

Cite

Share

P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.

Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H, Hashimoto M. Takenouchi T, et al. Among authors: sekiyama k. Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):91-6. doi: 10.1007/s00005-010-0069-y. Epub 2010 Feb 9. Arch Immunol Ther Exp (Warsz). 2010. PMID: 20143170 Review.

Cite

Share

10

Cite

Share

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M. Fujita M, et al. Among authors: sekiyama k. J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. J Neurol. 2009. PMID: 19711118 Review.

Cite

Share